
    
      The drug being evaluated in this study is called Enantone (leuprorelin). Enantone is used to
      treat children who have CPP. This study will look at long term safety and efficacy of
      leuprorelin in the treatment of Chinese participants with CPP.

      The study will enroll approximately 300 participants.

      All participants who have received leuprorelin 30 mcg/kg to <90 mcg/kg or 90 mcg/kg to 180
      mcg/kg per body weight, injection, subcutaneously, every 4 weeks up to at least 9 continuous
      months during the index period from September 1st 1998 to September 30th 2018 will be
      observed.

      This multi-center trial will be conducted in China. Data will be collected over period of 20
      months.
    
  